{"name":"CannaMore Biotechs","slug":"cannamore-biotechs","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CBD, synthetic form","genericName":"CBD, synthetic form","slug":"cbd-synthetic-form","indication":"Treatment-resistant epilepsy","status":"phase_2"}]}],"pipeline":[{"name":"CBD, synthetic form","genericName":"CBD, synthetic form","slug":"cbd-synthetic-form","phase":"phase_2","mechanism":"CBD, a synthetic form, interacts with the body's endocannabinoid system to produce therapeutic effects.","indications":["Treatment-resistant epilepsy","Multiple sclerosis spasticity"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPcXFKdVpGTHBlaHRZenVhekMyM0ZWRmVOS2FOem5KcVdHTFBUZzNIMmFOWTFub1NsU1lpYXE4bzlGUVFJSXFCZ0lsN0lkZVMzc2Etd05TTmZKSHdQdjZEMmpHb1gtYVBNa1NkZU1MN2tTSENVa3hxbFZkRkdGdnB3TktB?oc=5","date":"2024-07-23","type":"trial","source":"Clinical Trials Arena","summary":"CannaMore Biotechs concludes trial of CBD-based treatment for ulcerative colitis - Clinical Trials Arena","headline":"CannaMore Biotechs concludes trial of CBD-based treatment for ulcerative colitis","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}